Business
Equillium Announces Oral Presentation at the Italian Society of Experimental Hematology
Translational data demonstrates itolizumab’s impact on effector T cell function in acute graft-versus-host disease LA JOLLA, Calif.--(BUSINESS WIRE)--
About this update from Equillium, Inc.
[{"type":"text","content":"\nTranslational data demonstrates itolizumab’s impact on effector T cell function in acute graft-versus-host disease\n\n LA JOLLA, Calif.--(BUSINESS WIRE)--\nEquillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced an oral presentation at the 2022 National Congress of the Italian Society of Experimental Hematology in Rome, Italy. The presentation analyzes data from the immune reconstitution of 95 adult patients that underwent allogeneic hematopoietic cell transplantations at the Dana-Farber Cancer Institute between September 2018 and January 2020, demonstrating itolizumab’s ability to inhibit pathogenic T cell proliferation in patients with acute graft-versus-host disease (aGVHD).\n\n“The translational work presented specifically characterizes CD6 expression levels and demonstrates the suppressive effect of itolizumab on the activity of CD4 and CD8 T cells from transplant patients with aGVHD,” said Jerome Ritz, M.D., executive director of the Connell and O’Reilly Families Cell Manipulation Core Facility at Dana-Farber Cancer Institute and professor of medicine at Harvard Medical School. “The data highlights the important role of the CD6-ALCAM pathway in modulating effector T cell function and further supports the progress into a Phase 3 study of itolizumab in first-line aGVHD.”\n\nItolizumab is a first-in-class anti-CD6 monoclonal antibody that selectively targets the CD6-ALCAM pathway, which plays a central role in modulating the activity and trafficking of the pathogenic T cells driving a number of immuno-inflammatory diseases.\n\n\n\nPresentation ID:\n\n\n\n\n\nNo.14\n\n\n\n\n\nCategory:\n\n\n\n\n\nImmunotherapy and transplantation\n\n\n\n\n\nAbstract Title:\n\n\n\n\n\nThe Inhibition of the CD6-ALCAM Co-Stimulatory Pathway of T Lymphocytes Through the use of the Anti-CD6 Monoclonal Antibody Itolizumab for the treatment of Acute Graft-Versus-Host Disease After Hematopoietic Stem Cell Transplantation\n\n\n\n\n\nFirst Author:\n\n\n\n\n\nBenedetta Rambaldi, M.D., Research Fellow in Medicine, Dana-Farber Cancer Institute, Department of Hematologic Malignancies and Harvard Medical School\n\n\n\n\nKey Highlights, Summary and Conclusions from Oral Presentation:\n\n\nCD6+ T cells reco...